| Name | Title | Contact Details |
|---|
NFW is a circularity platform for plastic-free performance materials. NFW follows three Ground Rules in everything we develop: start well, stay clean, end well. While nearly everything in the built world relies on some type of plastic that began as crude oil and that will become plastic pollution, we are establishing a new material reality. We believe all materials should begin and end as nutrients, ready for the next growth cycle—true circularity. Our multi-material platform serves a wide range of industries—from fashion and footwear to automotive and upholstery. NFW technology embeds seamlessly into existing supply chains, enabling the worlds most iconic brands to design and scale products with high-performance, plastic-free materials. NFW makes global brands more sustainable, empowering them to create without plastics. Alongside the boldest brands and visionary designers, we are pioneering a naturally circular, post-oil economy.
Flynn Restaurant operates franchise over 1200 restaurants in the U.S. under the Applebees, Arbys, Panera and Taco Bell Brands.
DRAXXON is a global manufacturer of specialty vehicle solutions, integrating cutting edge technology into vans, SUVS, trailers, and ruggedized Pelican case configurations.
We are a full-service agency providing insurance in personal, business, bonding, farm, life, and flood. Our staff has over 400 years of experience. We pride ourselves on customer service and knowledge of the products we offer. Stop in to one of our North Dakota or Minnesota locations.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.